RT Journal Article
SR Electronic
T1 Mitomycin C plus Capecitabine (MiXe) in Anthracycline- and Taxane-pretreated Metastatic Breast Cancer. A Multicenter Phase II Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2871
OP 2875
VO 27
IS 4C
A1 MAISANO, ROBERTO
A1 CARISTI, NICOLA
A1 MARE, MARZIA
A1 RAFFAELE, MARIO
A1 IORFIDA, MONICA
A1 MAFODDA, ANTONINO
A1 ZAVETTIERI, MARIA
A1 NARDI, MARIO
YR 2007
UL http://ar.iiarjournals.org/content/27/4C/2871.abstract
AB Background: Capecitabine is considered the treatment of choice for anthracycline- and taxane-pretreated metastatic breast cancer. Mitomycin C seems to improve the activity of capecitabine by up-regulation of thymidine phosphorylase. Patients and Methods: Fifty-five women with metastatic breast cancer previously treated with anthracycline-taxane were treated with mitomycin C 10 mg/m2 on day 1 every six weeks and capecitabine 1000 mg/m2 on days 2-15 every three weeks. Results: An overall response rate of 38% was found, consisting of 3 (5%) complete responses (CR) and 18 (33%) partial responses (PR); 8 patients (14%) had a stable disease (SD) for more than 4 months. The combination was well-tolerated, with the main toxicities being neutropenia, diarrhea and fatigue; other toxicities were of mild to moderate intensity without impairment in the quality of life of the patients. Conclusion: Capecitabine is confirmed as the drug of choice in the treatment of anthracycline- and taxane-pretreated metastatic breast cancer and its combination with mitomycin appears to improve its efficacy.